Breaking News, Trials & Filings

Seqirus Receives FDA Approval for New Mfg. Process

Will enable Seqirus to double current production levels of FLUCELVAX® QUADRIVALENT for supply in the 2019/20 flu season

Seqirus announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina.  The approval will enable Seqirus to more than double current production levels of FLUCELVAX® QUADRIVALENT for supply in the 2019/20 influenza season.  The approval came as Seqirus announced its FY18 earnings, which showed the company has delivered on its commitment to reach profitability just three years after it was created. The results represent more than $300 million t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters